News
IRON
74.78
+6.58%
4.62
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 2d ago
Disc Medicine COO Jonathan Yen-Wen Yu disposes of 9,700 common shares worth $704,795
PUBT · 4d ago
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
PR Newswire · 4d ago
Disc Medicine Stockholders Approve Governance and Executive Pay
TipRanks · 4d ago
Disc Medicine shareholders approve advisory executive pay vote
PUBT · 4d ago
Disc Medicine CEO John Quisel disposes of common shares worth $2.38 million
PUBT · 5d ago
Weekly Report: what happened at IRON last week (0615-0619)?
Weekly Report · 6d ago
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
PR Newswire · 06/19 18:07
Noteworthy Wednesday Option Activity: IRON, GS, AVGO
NASDAQ · 06/17 19:33
Disc Medicine: The CRL Has Created A Cleaner Bull Case
Seeking Alpha · 06/17 14:38
Disc Medicine Price Target Raised to $85.00/Share From $80.00 by Morgan Stanley
Dow Jones · 06/16 13:38
Disc Medicine Is Maintained at Overweight by Morgan Stanley
Dow Jones · 06/16 13:38
Wedbush Sticks to Its Buy Rating for Disc Medicine (IRON)
TipRanks · 06/16 13:36
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $85
Benzinga · 06/16 13:28
Analysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Gilead Sciences (GILD)
TipRanks · 06/16 11:51
Disc Medicine price target raised to $85 from $80 at Morgan Stanley
TipRanks · 06/15 20:05
Disc Medicine posts corporate deck highlighting bitopertin in EPP pipeline progress
PUBT · 06/15 17:10
Analysts Are Bullish on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), Disc Medicine (IRON)
TipRanks · 06/15 16:20
Weekly Report: what happened at IRON last week (0608-0612)?
Weekly Report · 06/15 09:10
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
PR Newswire · 06/14 13:46
More
Webull provides a variety of real-time IRON stock news. You can receive the latest news about Disc Medicine Inc through multiple platforms. This information may help you make smarter investment decisions.
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.